Education
About Us
Working with TipRanks
Follow Us
Bone Therapeutics (GB:0R55)
:0R55
0R55 Stock Chart & Stats
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume4.75K
Average Volume (3M)7.35M
Market Cap
€1.63M
Enterprise ValueN/A
Total Cash (Recent Filing)€816.00K
Total Debt (Recent Filing)€26.79M
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Jun 30, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding652,862,300
10 Day Avg. Volume7,348,867
30 Day Avg. Volume7,348,867
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bone Therapeutics News
0R55 FAQ
What was Bone Therapeutics’s price range in the past 12 months?
Bone Therapeutics lowest share price was <€0.01 and its highest was €0.01 in the past 12 months.
What is Bone Therapeutics’s market cap?
Bone Therapeutics’s market cap is €1.63M.
When is Bone Therapeutics’s upcoming earnings report date?
Bone Therapeutics’s upcoming earnings report date is Jun 30, 2025 which is 92 days ago.
How were Bone Therapeutics’s earnings last quarter?
Currently, no data Available
Is Bone Therapeutics overvalued?
According to Wall Street analysts Bone Therapeutics’s price is currently Overvalued.
Does Bone Therapeutics pay dividends?
Bone Therapeutics pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Bone Therapeutics dividends here
What is Bone Therapeutics’s EPS estimate?
Bone Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bone Therapeutics have?
Bone Therapeutics has 652,862,300 shares outstanding.
What happened to Bone Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bone Therapeutics?
Currently, no hedge funds are holding shares in GB:0R55
Company Description
Bone Therapeutics
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.